|
| ![]() Sygnature today announced the appointment of Dr Michael Knaggs as Head of Computational Chemistry. Dr Simon Hirst CEO, commented, 'I welcome Mick to Sygnature, he is a great addition to our scientific team and has joined at an opportune time.' Mick has over 10 years computational chemistry experience in the pharmaceutical industry and academia in the UK and USA. He has good experience of understanding virtual screening projects ( structure-based and ligand-based approaches) in a variety of targets, pharmacophore modelling, QSAR and library design; as well as protein modelling and simulation work. | |
|
| ![]() Sygnature Chemical Services Ltd., a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and Cyprotex Discovery Ltd., a world renowned pre-clinical discovery and development CRO with a core focus on ADME/PK, today announced they have entered a strategic alliance. Under the terms of the agreement, Sygnature and Cyprotex will collaborate to provide a fully integrated discovery chemistry/DMPK service to accelerate their clients' drug discovery projects into development. | |
|
| ![]() Sygnature and RespiVert yesterday provided an update on their research collaboration, first announced in January 2008. Under the terms of the agreement Sygnature have provided a comprehensive medicinal chemistry discovery platform for two of RespiVert's leading programmes aimed at identifying novel therapeutic agents for the treatment of poorly controlled, steroid refractory pulmonary disease | |
|
| ![]()
Sygnature Chemical Services Ltd. and Heptares Therapeutics Ltd., a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), today announced that they have entered into a contract chemistry collaboration in drug discovery. Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs™, Stabilised Receptors).
| |
|
| ![]() Sygnature Chemical Services Ltd has been awarded a £390,000 Grant for Business Investment (GBI) award by the East Midlands Development Agency (emda) and the European Regional Development Fund (ERDF). GBI is a discretionary scheme which provides a capital grant to businesses based in England to support sustainable investment. Its aim is to help businesses expand, rationalise, modernise or diversify. | |
|
| ![]() Sygnature has recently added the FlowSyn TM continuous flow reactor from UNIQSIS to its technology capability and is the first CRO in the UK to invest in the UNIQSIS system. | |
|
| ![]()
Dr Jonathan Williams becomes Director of Operations following four years with the company, first as Principal Research Chemist and more recently as Research Leader. Jonathan is a highly regarded medicinal chemist who also brings broad management experience to the Board.
Dr Paul Clewlow joined Sygnature on April 1st 2009 as Senior Vice-President,Business Development. The rapid growth of Sygnature Chemical Services means that Paul's strategic expertise will be invaluable in helping to chart the future direction of the Company. | |
|
| ![]() Due to an unprecedented demand for it's contract medicinal chemistry services, Sygnature has already outgrown the purpose- designed and built laboratory and office space occupied during the £1m expansion announced in April 2008, and expanded into additional space within BioCity's state-of-the-art Laurus building. | |
|
| ![]() Sygnature Chemical Services is participating in the Drug Discovery Chemistry conference to showcase it's medicinal and synthetic chemistry expertise. This years event, organised by Cambridge Healthtech Institute, is taking place at the San Diego Hilton Resort. Dr Simon Hirst CEO and Dr Paul Clewlow, Senior Vice-President, Business Development will be discussing how Sygnature can accelerate clients drug discovery programmes. | |
|
| ![]() Sygnature is sponsoring this years Compound Library meeting in Düsseldorf, Germany, 6th-8th October 2008. CEO, Dr Simon Hirst will be presenting Sygnature's approach to Hit-to-lead chemistry under the expanded remit of the conference which now covers library design and Hit-to-lead optimization. | |
|
| ![]() Sygnature announced today that it has commenced work on a new research facility at BioCity Nottingham, UK. The £1m expansion is the start of a two phase project to create two new state-of-the-art chemistry laboratories to house medicinal chemistry teams. The facility, due to complete in August 2008 will be accompanied by further growth of the medicinal chemistry group. | |
|
| ![]() Today Sygnature announced that RespiVert Limited has selected Sygnature Chemical Services Ltd to support two new discovery collaborations. Under the agreement Sygnature will provide medicinal chemistry resources to the programs aimed at identifying novel approaches to respiratory diseases. | |
|
|